



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE  
DELLA RICERCA

## Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Supplementation with dairy matrices impacts on homocysteine levels and gut microbiota composition of hyperhomocysteinemic mice

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Zinno, P., Motta, V., Guantario, B., Natella, F., Roselli, M., Bello, C., et al. (2020). Supplementation with dairy matrices impacts on homocysteine levels and gut microbiota composition of hyperhomocysteinemic mice. EUROPEAN JOURNAL OF NUTRITION, 59, 345-358 [10.1007/s00394-019-01911-y].

*Availability:*

This version is available at: <https://hdl.handle.net/11585/796111> since: 2024-10-25

*Published:*

DOI: <http://doi.org/10.1007/s00394-019-01911-y>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

(Article begins on next page)

# European Journal of Nutrition

## Supplementation with dairy matrices impacts on homocysteine levels and gut microbiota composition of hyperhomocysteinemic mice --Manuscript Draft--

<b>Manuscript Number:</b>	
<b>Full Title:</b>	Supplementation with dairy matrices impacts on homocysteine levels and gut microbiota composition of hyperhomocysteinemic mice
<b>Article Type:</b>	Original Contribution
<b>Keywords:</b>	Fermented food; folate; homocysteine; microbiome
<b>Corresponding Author:</b>	Chiara Devirgiliis Council for Agricultural Research and Economics (CREA) Rome, ITALY
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Council for Agricultural Research and Economics (CREA)
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Paola Zinno
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Paola Zinno Vincenzo Motta Barbara Guantario Fausta Natella Marianna Roselli Cristiano Bello Raffaella Comitato Domenico Carminati Flavio Tidona Aurora Meucci Paola Aiello Giuditta Perozzi Fabio Virgili Paolo Trevisi Raffaella Canali Chiara Devirgiliis
<b>Order of Authors Secondary Information:</b>	
<b>Funding Information:</b>	Ministero delle Politiche Agricole Alimentari e Forestali (DM 12487/7303/11) Dr. Chiara Devirgiliis
<b>Abstract:</b>	Purpose Several studies highlighted a correlation between folic acid deficiency and high plasma homocysteine concentration, which is considered a risk factor for multifactorial diseases. Natural folates represent an emerging alternative strategy to supplementation with synthetic folic acid, whose effects are controversial. The present work was therefore performed in hyperhomocysteinemic mice to study the impact of

	<p>supplementation with either milk, or fermented milks enriched in natural folates, produced by selected lactic acid bacteria, on plasma homocysteine levels and faecal microbiota composition.</p> <p>Methods Forty mice were divided into six groups, two of which fed control or folic acid deficient diets. The remaining four groups were fed folic acid deficient diet and then shifted to: a standard control diet or a folic acid deficient diet supplemented with folate-enriched fermented milk, fermented milk, or unfermented milk.</p> <p>Results Supplementation with dairy matrices restored homocysteine levels in folic acid-deficient mice, although impacting differently on hepatic S-adenosyl-methionine levels, and also determined specific, significant variations in faecal microbiota composition. Moreover, LEfSe analysis identified bacterial biomarker genera characterising each group of mice.</p> <p>Conclusions Taken together, our results highlighted the efficacy of natural folates. Among the three dairy matrices, folate-enriched fermented milk resulted the most effective in restoring both homocysteine and S-adenosyl-methionine levels to the control conditions. The possible relationships between the presence of bacterial biomarkers and hyperhomocysteinemia, as well as the possible implications of such microorganisms in folate metabolism, are currently under investigation.</p>
<p><b>Suggested Reviewers:</b></p>	<p>Thomas Thymann Kobenhavns Universitet ttn@nexs.ku.dk Expertise in animal and human nutrition</p> <p>Jordi Estellè Institut National de la Recherche Agronomique jordi.estelle@inra.fr Expertise in characterization of complex microbial communities</p> <p>Maria De Angelis Universita degli Studi di Bari Aldo Moro maria.deangelis@uniba.it Expertise in food microbiology</p> <p>Carlotta De Filippo Italian National Research Council carlotta.defilippo@ibba.cnr.it Expertise in diet-microbiota interactions</p>

[Click here to view linked References](#)

1 **Supplementation with dairy matrices impacts on homocysteine levels and gut microbiota**  
2 **composition of hyperhomocysteinemic mice**

3 Paola Zinno<sup>1a</sup>, Vincenzo Motta<sup>2a</sup>, Barbara Guantario<sup>1</sup>, Fausta Natella<sup>1</sup>, Marianna Roselli<sup>1</sup>,  
4 Cristiano Bello<sup>1</sup>, Raffaella Comitato<sup>1</sup>, Domenico Carminati<sup>3</sup>, Flavio Tidona<sup>3</sup>, Aurora Meucci<sup>3</sup>,  
5 Paola Aiello<sup>1</sup>, Giuditta Perozzi<sup>1</sup>, Fabio Virgili<sup>1</sup>, Paolo Trevisi<sup>2</sup>, Raffaella Canali<sup>1\*</sup> and Chiara  
6 Devirgiliis<sup>1\*</sup>

7 <sup>1</sup>*Research Centre for Food and Nutrition, CREA (Council for Agricultural Research and*  
8 *Economics), Via Ardeatina 546, 00178 Rome, Italy*

9 <sup>2</sup>*Department of Agricultural and Food Sciences (DISTAL), University of Bologna, Viale Fanin*  
10 *46, 40127 Bologna, Italy*

11 <sup>3</sup>*Research Centre for Animal Production and Aquaculture, CREA (Council for Agricultural*  
12 *Research and Economics), Via A. Lombardo 11, 26900 Lodi, Italy*

13

14 <sup>a</sup>The authors contributed equally to the work

15 \*Corresponding authors:

16 Chiara Devirgiliis, Research Centre for Food and Nutrition, CREA, Via Ardeatina 546, 00178  
17 Rome, Italy; e-mail: chiara.devirgiliis@crea.gov.it; phone n.: +390651494647.

18 ORCID: 0000-0002-7114-7726

19

20 Raffaella Canali, Research Centre for Food and Nutrition, CREA, Via Ardeatina 546, 00178  
21 Rome, Italy; e-mail: raffaella.canali@crea.gov.it; phone n.: +390651494497.

22 ORCID: 0000-0003-0012-4831

23

24

25 **Keywords**

26 Fermented food, folate, homocysteine, microbiome

27

28

29 **Abstract**

30 *Purpose* Several studies highlighted a correlation between folic acid deficiency and high plasma  
31 homocysteine concentration, which is considered a risk factor for multifactorial diseases. Natural  
32 folates represent an emerging alternative strategy to supplementation with synthetic folic acid,  
33 whose effects are controversial. The present work was therefore performed in  
34 hyperhomocysteinemic mice to study the impact of supplementation with either milk, or  
35 fermented milks enriched in natural folates, produced by selected lactic acid bacteria, on plasma  
36 homocysteine levels and faecal microbiota composition.

37 *Methods* Forty mice were divided into six groups, two of which fed control or folic acid deficient  
38 diets. The remaining four groups were fed folic acid deficient diet and then shifted to: a standard  
39 control diet or a folic acid deficient diet supplemented with folate-enriched fermented milk,  
40 fermented milk, or unfermented milk.

41 *Results* Supplementation with dairy matrices restored homocysteine levels in folic acid-deficient  
42 mice, although impacting differently on hepatic S-adenosyl-methionine levels, and also  
43 determined specific, significant variations in faecal microbiota composition. Moreover, LEfSe  
44 analysis identified bacterial biomarker genera characterising each group of mice.

45 *Conclusions* Taken together, our results highlighted the efficacy of natural folates. Among the  
46 three dairy matrices, folate-enriched fermented milk resulted the most effective in restoring both  
47 homocysteine and S-adenosyl-methionine levels to the control conditions. The possible  
48 relationships between the presence of bacterial biomarkers and hyperhomocysteinemia, as well  
49 as the possible implications of such microorganisms in folate metabolism, are currently under  
50 investigation.

51

## 52 **Introduction**

53 Nutritional deficiencies, especially those related to B-vitamins including folic acid that lead to  
54 high plasma homocysteine (Hcy) concentration [1], are considered a risk factor for various  
55 diseases. Hcy is a sulphur-containing amino acid intermediate that stands at the junctions of  
56 trans-methylation, re-methylation and trans-sulphuration pathways. Hcy has been associated to  
57 endothelial dysfunction [2], therefore, its prompt removal is required to prevent harmful  
58 accumulation. Under well-balanced dietary regimen, its clearance occurs either by re-  
59 methylation to methionine or by catabolism to cysteine. Re-methylation, catalysed by methionine  
60 synthase (MS), can occur via cobalamin/vitamin B12 dependent transfer of methyl groups from  
61 5'-methyl tetrahydrofolate (5-MTHF), or through the betaine-homocysteine S-methyltransferase  
62 (BHMT) reaction that uses betaine (a choline metabolite) as methyl donor (folate independent re-  
63 methylation). In the trans-methylation pathway, methionine is condensed to ATP to yield S-  
64 adenosyl-methionine (SAM), representing the primary methyl donor in biological processes. The  
65 removal of methyl group from SAM during methylation reactions generates S-  
66 adenosylhomocysteine (SAH), whose hydrolysis forms Hcy. Finally, catabolism of Hcy uses the  
67 trans-sulphuration pathway, via vitamin B6/Cystathionine beta synthase (CBS) catalysis.

68 Moderately elevated levels of Hcy resulting from variation in gene-nutrient interactions are  
69 mainly due to polymorphisms in the genes encoding for re-methylation enzymes, such as  
70 methylenetetrahydrofolate reductase (MTHFR) and/or MS, combined with low B vitamin status  
71 (folate, B6 or B12). Dietary pattern alone can also have an effect on Hcy levels, being  
72 significantly and inversely correlated with serum folate and vitamin B12 or B6 levels. Folate  
73 status is considered the most important marker of impaired Hcy methylation [3] [4,5].

74 As mentioned, hyperhomocysteinemia is associated to vascular endothelium alterations and is  
75 therefore considered a risk factor for complex and multifactorial disorders including  
76 cardiovascular disease and neurological dysfunction [6]. However, recent reviews and meta-  
77 analyses have reported the absence of a significant effect of Hcy-lowering interventions (with  
78 folic acid and/or B vitamin supplementation) on the incidence of myocardial infarction, or death  
79 from any cause, or cognitive decline, with the only exception of stroke [7-11].

80 At present, the main expedient strategies to counteract hyperhomocysteinemia include the  
81 supplementation or food fortification with synthetic folic acid. Conversely to naturally occurring  
82 folates, mainly represented by tetrahydrofolate (THF) and its derivatives [12,13], synthetic folic  
83 acid needs to be converted to the biologically active form (THF) by dihydrofolate reductase  
84 (DHFR) to enter the folate cycle. The conversion of folic acid to THF is a slow process because  
85 DHFR has reduced metabolic capacity that increases the risk of accumulation of unmetabolised

86 folic acid in blood, thus limiting the benefit of the use of synthetic folic acid [13,14]. Recent  
87 evidence indeed suggests that the unmetabolised folic acid can be harmful, and high folic acid  
88 intake was shown to exert a series of potentially toxic effects including impairment of normal  
89 immune function [15,16]; cancer development and progression [17-20]; alteration of DHFR  
90 enzymatic activity [14] and of liver lipid metabolism [21] as well as development of neuropathy  
91 risk [22]. A growing number of studies are therefore focusing on the application of alternative  
92 strategies based on the use of natural folates.

93 Several Lactic Acid Bacteria (LAB) or Bifidobacteria strains involved in dairy fermentations are  
94 able to synthesise natural folates that are released into the food matrix [23,24] and are therefore  
95 promising candidates to revert folate deficiency and the associated metabolic alterations [25-27]  
96 [28,29]. Therefore, the aim of this work was to evaluate if supplementation with dairy matrices,  
97 including fermented milk enriched in natural folates produced by suitably selected LAB strains,  
98 could affect plasma Hcy levels in hyperhomocysteinemic mice. Moreover, as the majority of  
99 available studies did not take into account the effect of the dietary interventions on intestinal  
100 microbiota composition, or the possible colonisation capacity exerted by fermentative microbes  
101 (which could provide an important additional endogenous source of folates [30]), we also  
102 examined the impact of supplementations on faecal microbiota composition.

103

## 104 **Materials and Methods**

### 105 **Bacterial strains and growth conditions**

106 The LAB strains employed in this study were isolated from Italian dairy products and stored in  
107 the LAB collection of CREA-ZA, Lodi (Italy). *Streptococcus thermophilus* 563 was cultivated in  
108 M17 broth (Merck, Darmstadt, Germany) supplemented with 1% lactose, at 42 °C in aerobic  
109 conditions. *Lactobacillus delbrueckii* subsp. *lactis* 1021 and *Lactobacillus helveticus* 989 were  
110 cultivated in MRS (De Man, Rogosa, Sharpe, Merck) at 42 °C in anaerobic conditions. *L.*  
111 *rhamnosus* ATCC7469 was cultivated in MRS at 37 °C in aerobic conditions.

112

### 113 **Fermented milk preparation and analyses**

114 Skimmed milk powder was used as starting food matrix (Oxoid, Basinstoke, England). It was  
115 reconstituted with deionised water, steam sterilised, and subsequently inoculated with bacterial  
116 strains, previously selected for the ability to produce folate. In particular, the folate-enriched  
117 fermented milk (FFM) was obtained by co-cultivating two folate-producing strains belonging to  
118 different genera, *Streptococcus thermophilus* 563 and *Lactobacillus delbrueckii* subsp. *lactis*  
119 1021. To enhance folate accumulation, fermentation of FFM was carried out at 42 °C in two  
120 steps: 4 h at controlled pH 6.0, obtained by addition of sterile 5 N NaOH to the culture medium,  
121 followed by uncontrolled overnight fermentation (20 h). Fermented milk (FM) was produced  
122 using the low-folate producer strain *Lactobacillus helveticus* 989, incubated at 42 °C for 24 h.  
123 Sterile reconstituted skimmed milk lacking bacterial strains was used as unfermented milk (M).  
124 After preparation, fermented milks were lyophilised and kept frozen until addition to the diets.  
125 All milk supplements, including M, were subjected to the following assays: bacterial cell counts  
126 ( $\log_{10}$ CFU/ml) under anaerobic conditions to evaluate the growth of *Lactobacillus* (in MRS agar,  
127 42 °C, 48 h), and *S. thermophilus* strains (in M17 agar, 42 °C, 48 h); pH determination by means  
128 of the Portamess 913 pH meter (Knick Elektronische, Germany); lactose, glucose, galactose,  
129 citric acid and lactic acid content (g/100 g) according to the HPLC method described by [31].  
130 Folate content was assayed by a microbiological assay using *L. rhamnosus* ATCC7469 as  
131 indicator strain, since it is auxotrophic for folic acid [32]. Folate concentration (ng/ml) was  
132 determined using folic acid (Sigma Aldrich, Italy) as standard to build the calibration curve. All  
133 determinations were done in duplicate.

134

### 135 **Experimental design, animals and diets**

136 A total of 40, 6-weeks old C57BL/6J male mice, obtained from Charles River Laboratories  
137 (Como, Italy), were kept at 23 °C with a 12 h light-dark cycle and fed *ad libitum* with a standard



138 laboratory diet (4RF21, Mucedola, Milan, Italy, [www.mucedola.it](http://www.mucedola.it)). Mice had free access to food  
139 and water throughout the experiments. Food intake and body weight were recorded every other  
140 day and once a week, respectively. After one week of adaptation, animals were randomly divided  
141 into 6 groups (6-8 mice per group), housed individually and supplemented as reported in Figure  
142 1: the first 2 groups were fed control diet or folic acid deficient diet for 10 weeks (C: Control and  
143 FD: Folic acid Deficient, respectively). The remaining 4 groups were fed FD diet for the first 5  
144 weeks and then shifted for additional 5 weeks to: a standard control diet (R: Repleted) or a FD  
145 diet supplemented with either folate-enriched fermented milk (FFM: Folate Fermented Milk), or  
146 fermented milk (FM: Fermented Milk), or unfermented milk (M: Milk). The experimental  
147 protocol is schematically represented in Figure 1.

148 The C diet was a modified version of the AIN-93M maintenance diet for rodents [33], where  
149 casein was replaced with a casein-like aminoacid mix, and contained 0.002 g/kg folic acid, 2.5  
150 g/kg choline and 3.6 g/kg methionine (Table 1). Hyperhomocysteinemia was achieved by  
151 feeding mice with FD diet that was depleted of folic acid and choline (0 g/kg) to minimise the  
152 content of the MS and BHMT enzyme substrates, and lowered in methionine content with  
153 respect to C diet (1.8 g/kg). All purified ingredients, except the lyophilised milks, were prepared  
154 and provided by Laboratori Dottori Piccioni s.r.l. (Gessate, Milan, Italy). Milk-supplemented  
155 diets were appropriately balanced for protein and complex carbohydrate content (Table 1).

156 At the end of the experimental period, feces were collected and stored at -80 °C for microbiome  
157 analysis. Following overnight fasting, mice were anaesthetised by intraperitoneal injection of  
158 pentobarbital (10 mg/kg), blood was drawn via cardiac puncture, liver was quickly excised and  
159 immediately immersed in liquid nitrogen in pieces of approximately 100 mg. Serum was  
160 prepared from blood and stored at -80 °C until further analysis. All experimental procedures  
161 involving animals complied with the European Guidelines for the Care and Use of Animals for  
162 Research Purposes (Directive 2010/63/EU), and protocols were approved by the Ethical  
163 Committee of the Food and Nutrition Research Center and by the National Health Ministry,  
164 General Direction of Animal Health and Veterinary Drugs (agreement n° 268/2016). All efforts  
165 were made to minimise suffering of the animals.

166 An additional, pilot group of 15 mice fed C (n = 8) and FD (n = 7) diets was employed for  
167 preliminary analysis aimed at evaluating homocysteine levels after 5 weeks of depletion, as well  
168 as faecal microbiota composition.

169

## 170 **Plasmatic Hcy determination**

171 Plasma total Hcy was measured by LC-MS/MS according to [34]. Briefly, 50 µl of plasma were  
172 mixed with 25 µl of 10 µg/ml d4-Hcy (internal standard) and 50 µl of 500 mM dithiothreitol, and  
173 the mixture was kept at room temperature for 15 min. Proteins were precipitated by adding 25 µl  
174 of 70% trichloroacetic acid and the mixture was centrifuged for 8 min at 13.000 rpm (4 °C).  
175 Supernatants were appropriately diluted, filtered through 0.20 µm syringe PVDF filters and  
176 injected.

177 The analysis was performed with an HPLC system interfaced to an AB Sciex 3200 Q-Trap  
178 instrument working in MRM mode. LC analyses were conducted using a system equipped with a  
179 PE200 binary pump (Perkin-Elmer, USA). Samples (5 µl) were injected into a Waters XBridge  
180 Phenyl column (Waters, USA) (150x2.1 mm, i.d. 3.5 µm) and eluted at a flow rate of 0.2  
181 ml/min. Mobile phase A was water and mobile phase B was acetonitrile, both acidified with  
182 0.1% formic acid. Elution was carried out using a gradient beginning at 30% B and changing to  
183 50% B in 2 min, then remaining at 50% B for 5 min and finally to 30% B in 1 min. The column  
184 was kept at 25 °C by a Peltier Column Oven Series 200 (Perkin-Elmer, USA). MS detection was  
185 performed in ESI positive ion mode. Ion spray voltage was set to 4500 V, source temperature  
186 was held at 600 °C, declustering potential to 35 kV, entrance potential to 9 kV and collision  
187 energy to 15 kV. Transitions for Hcy and d4-Hcy were monitored at 136/90 and 140/94 m/z,  
188 respectively. Data acquisition and processing were performed using Analyst software 1.5.1.

189

### 190 **Hepatic SAM measurement**

191 Hepatic SAM measurement was performed according to [35,36] with some modifications.  
192 Because of the instability of SAM in tissue, sample preparation and SAM analysis were  
193 performed the same day of the excision. Liver was homogenised and deproteinised in ice cold  
194 0.4 M perchloric acid. The homogenate was centrifuged 10 min at 7000g and the supernatant  
195 was mixed with 1µM of [<sup>2</sup>H<sub>3</sub>]-SAM (Biochemical Research 2000 S.r.l., Rome, Italy) used as  
196 internal standard. The solution was applied to an OASIS solid-phase-extraction (SPE) column  
197 (Waters, Milford, MA, USA), which was conditioned with methanol and 10 mM SDS pH 2.1  
198 (50:50, v/v). The column was rinsed with H<sub>2</sub>O and Methanol 15% (50:50, v/v) and sample eluted  
199 with methanol.

200 Quantitative on-line HPLC-ESI-MS/MS analyses were performed using HPLC system interfaced  
201 to an Applied Biosystems (Foster City, CA, USA) API3200 Q-Trap instrument working with  
202 triple quadrupole analyser in Multiple Reaction Monitoring (MRM) mode. LC analyses were  
203 conducted using a system equipped with a 200 binary pump (Perkin-Elmer, USA). Samples were  
204 injected (10 µl) into a C18 analytical column (2,1x150 mm; 3 µm bead size; Fortis Technologies

205 Ltd, Cheshire, UK) eluted at flow rate of 0.25 ml min<sup>-1</sup>. Mobile phase A was H<sub>2</sub>O containing  
206 0.1% formic acid while mobile phase B was acetonitrile containing 0.1% formic acid. Elution  
207 was carried out using a gradient commencing at 100% B for 10 min, then changing to 10% B in  
208 17 min and finally returning to 100% B. The flow from the chromatograph was injected directly  
209 into the ESI source. The API 3200 ES source was tuned by infusing SAM (1 µg ml<sup>-1</sup>) into the  
210 source at a flow rate of 10 ml min<sup>-1</sup>. The MS operated with an electrospray voltage at 4500V and  
211 with source temperature of 550°C. Nitrogen was used as ion spray (GS1), drying (GS2) and  
212 curtain gas at 60, 60 and 20 arbitrary units, respectively. The declustering potential (DP),  
213 collision energy (CE) and entrance potential (EP) were 30, 25 and 6, respectively. SAM and  
214 [<sup>2</sup>H<sub>3</sub>]-SAM were detected with MRM transition of 399/250 and 402/250, respectively. Data  
215 acquisition and processing were performed using Analyst software 1.5.1. The quantification was  
216 performed by using a calibration curve of standards.

217

#### 218 **DNA extraction from faecal samples**

219 Total DNA was extracted from 80 mg faecal samples with the QIAamp DNA Stool Mini Kit  
220 (Qiagen, Hilden, Germany) according to manufacturer's instructions. The Qiagen DNA  
221 extraction method used in this work was chosen as it was listed among the most reproducible  
222 kits, ensuring minimal influence on Next Generation Sequencing (NGS) data analysis [37].

223

#### 224 **NGS analysis**

225 NGS analysis was performed on faecal DNA samples collected at the end of treatments (Figure  
226 1). NGS including basic bioinformatic analysis was performed at Eurofins Genomics S.r.l.  
227 sequencing laboratories (Ebersberg, Germany) by Illumina MiSeq with chemistry v3. Partial 16S  
228 rRNA gene sequences were amplified using primer pairs targeting the V3-V5 region of the gene  
229 (Eurofins 16S standard protocol).

230

#### 231 **Bioinformatics**

232 One sample from treatment "M" was excluded from the analysis for insufficient yield in the  
233 sequencing process (< 10,000 reads). The reads from the remaining 39 samples were imported in  
234 QIIME v1.9.1 [38]. All sequences were quality checked ( $Q \geq 20$ ) and processed applying the  
235 open-reference Operational Taxonomic Units (OTU)-picking strategy with 97% sequence  
236 similarity. The reads were chimera checked with chimera slayer and representative sequences  
237 were taxonomy assigned against the Greengenes database V13\_8 with a 90% confidence  
238 threshold. Low count OTUs were removed with a threshold of 0.005% (on overall OTUs) [39].

239 The OTU table generated in QIIME was imported in R 3.3.2. The “Phyloseq” package [40] was  
240 used to construct the rarefaction curves (Figure S1), which show the plateau's achievement in all  
241 samples, suggesting that the sampling effort (sequencing depth) was adequate to describe the  
242 variability within the microbial communities analysed.

243 The package “Phyloseq” was also used to evaluate the variability within the bacterial  
244 communities (alpha diversity) calculating the Shannon Index. The dissimilarity between bacterial  
245 communities (beta diversity) were evaluated through Bray-Curtis distance, using the package  
246 “vegan” [41], and the distance matrix was plotted with Non Metric Multidimensional Scaling  
247 (NMDS).

248

### 249 **Statistical analysis on microbiota data**

250 The effect of treatments on alpha diversity (Shannon index) was evaluated by one-way ANOVA,  
251 followed by *post-hoc* Tukey-Kramer test in R package “TDK”. Differences with P values < 0.05  
252 were considered significant, and the Benjamini & Hochberg correction was applied for multiple  
253 comparison (Padj). Normal distribution and homogeneity of variance were assessed with  
254 Shapiro-Wilk and Levene’s tests, respectively, prior to the analysis. The effect of treatment on  
255 Bray-Curtis distance matrix (beta diversity) was evaluated by nonparametric MANOVA with the  
256 *adonis* function in R package “vegan”, followed by pairwise *adonis*. Differences with P values <  
257 0.05 were considered significant, and the Benjamini & Hochberg correction was applied for  
258 multiple comparison in pairwise *adonis* (Padj). The *adonis* procedure consists in a permutational  
259 multivariate analysis of variance (PERMANOVA), which is a hypothesis test on the partitioning  
260 of variation in multivariate datasets. The datasets are represented through distance matrices  
261 based on dissimilarity measures (Bray-Curtis in our case) and the response to one or more factors  
262 are assessed in an analysis of variance design with a permutational algorithm [42]. The  
263 differentially abundant genera were identified by linear discriminant analysis (LDA) effect size  
264 (LEfSe), an algorithm designed for biomarker discovery that identifies the significantly enriched  
265 taxa in different experimental groups [43], implemented in Calypso (version 8.20) web-  
266 application [44] using a threshold of 2 on the logarithmic ( $\log_{10}$ ) LDA score for discriminative  
267 genera. Briefly, the LEfSe procedure uses in the first step the factorial Kruskal-Wallis sum-rank  
268 test to detect taxa with significant ( $P < 0.05$ ) differential abundance with respect to the class of  
269 interest; then the biological consistency is assessed using a set of pairwise tests among groups  
270 using the Wilcoxon rank-sum test ( $P < 0.05$ ); finally the LDA is used to estimate the effect size  
271 of each differentially abundant taxon.

272

273 **Statistical univariate analysis**

274 Values in plots and tables represent means  $\pm$  SD. Prior to analysis, normal distribution and  
275 homogeneity of variance of all variables were controlled with Shapiro-Wilk and Levene's tests,  
276 respectively. Statistical significance was evaluated by one-way ANOVA, followed by *post-hoc*  
277 Tukey honestly significant difference (HSD) test, when normality and homogeneity of variance  
278 were verified. Otherwise, Kruskal-Wallis and *post-hoc* Dunn test, and Welch one-way ANOVA  
279 followed by Tamhane test were used. Differences with P values  $< 0.05$  were considered  
280 significant. Statistical univariate analysis was performed with the "Statistica" software package  
281 (version 5.0; Stat Soft Inc., Tulsa, OK) and with Microsoft Office Excel 2011 upgraded with  
282 XLSTAT (ver. 4 March 2014).

283

284 **Results**

285 **Nutritional and microbiological features of dairy matrices**

286 The relevant features of fermented milks (FFM and FM) and unfermented milk (M) are  
287 summarised in Table 2. Sugar levels reflected the metabolic activity of bacteria present in the  
288 fermented products, as compared to M: lactose, representing the main milk disaccharide, was  
289 detected in higher amounts ( $P < 0.01$ ) in M ( $4.35 \pm 0.01$  g/100 g) as compared to FFM and FM  
290 ( $2.57 \pm 0.02$  and  $3.37 \pm 0.02$  g/100 g, respectively). Lactose is the main substrate of lactic  
291 fermentation, and it is converted essentially into lactic acid, which was detected only in FFM and  
292 FM at  $1.24 \pm 0.01$  and  $1.29 \pm 0.02$  g/100 g, respectively. Lactate accumulation led to lower pH  
293 values in both FFM and FM samples (i.e. pH = 3.89 and 3.77, respectively) with respect to M,  
294 characterised by a pH close to neutrality (pH = 6.60) (Table 2). In order to render the food  
295 matrices used for supplementation as homogeneous as possible in terms of chemical and  
296 organoleptic features, M was acidified by the addition of lactic acid (0.12 g/g lyophilised milk)  
297 to obtain a pH value similar to that of fermented milks.

298 The level of natural folates found in M ( $16.90 \pm 0.31$  ng/g) was similar to that observed in the FM  
299 ( $19.40 \pm 8.77$  ng/g) (Table 2), whereas the FFM showed a 4-fold increase ( $70.33 \pm 15.44$  ng/g,  $P <$   
300  $0.01$ ), confirming the ability of the chosen bacterial strains to over-produce folates.

301 Viability of the bacterial strains in fermented milks was evaluated through plate counting. The  
302 two LAB strains present in the FFM product (i.e. *S. thermophilus* 563 and *L. delbrueckii* subsp.  
303 *lactis* 1021) were distinguished by colony morphologies and confirmed by microscopic  
304 observation. The results obtained showed that *S. thermophilus* 563 reached a titer of  $9.10 \pm 0.01$   
305  $\log_{10}$  CFU/ml in FFM, about one log higher than that observed for *L. delbrueckii* 1021, namely  
306  $8.48 \pm 0.03$   $\log_{10}$  CFU/ml (Table 2). The higher titer of *S. thermophilus* 563 could be ascribed to  
307 a faster growth during the first step of fermentation under pH-controlled conditions. The  
308 microbial titer of the single strain *L. helveticus* 989 in FM reached a comparable level to *L.*  
309 *delbrueckii* 1021 in FFM.

310

311 **Growth parameters**

312 Daily food consumption and body weight were monitored throughout the experimental period.  
313 No significant differences were observed in these two parameters among the different mice  
314 groups, with the exception of food intake of FM group, which resulted higher than that of FD  
315 group, although with a P value of 0.049. It must be pointed out that no differences in weight as  
316 well as in weight gain were observed between these two groups. Overall, these findings indicate

317 that the nutrient depletion characterising FD diet did not affect food intake, and that the milk-  
318 based diets retained a good palatability with respect to C diet (Table 3).

319

### 320 **Supplementation with milk-based food matrices reverts hyperhomocysteinemia**

321 Preliminary analysis performed on mice fed C and FD diet showed that Hcys levels were  
322 significantly increased (about 2 fold change,  $P < 0.05$ ) after 5 weeks of FD diet with respect to C  
323 (data not shown). At the end of treatments (10 weeks), supplementation with the R diet, as well  
324 as with the three dairy matrices (FM, FFM and M) resulted in a significant reduction of plasma  
325 Hcy levels, which reached similar values to those observed in the C group (Figure 2a). On the  
326 other hand, mice fed FD diet for 10 weeks showed a significant, much more pronounced increase  
327 (about 6.5 fold change) of plasma Hcy levels with respect to C group ( $P < 0.0001$ ).

328

### 329 **Milk-based food matrices supplementation shows different effects on hepatic SAM** 330 **synthesis**

331 As shown in Figure 2b, nutritional deficiencies associated to FD diet induced a slight but not  
332 significant reduction of liver SAM levels compared to C. Surprisingly, supplementation of mice  
333 with FM and M diets caused a significant increase of SAM compared to C ( $P < 0.05$ ), FD ( $P <$   
334  $0.0001$ ), FFM ( $P < 0.05$ ) or R ( $P < 0.05$ ) groups. On the other hand, FFM diet supplementation  
335 maintained SAM levels to those of R and C diet.

336

### 337 **Milk-based food matrices affect faecal microbiota composition**

338 The effects of FD diet and of the different food matrices on faecal microbiota composition were  
339 evaluated by assessing the relative abundance of the main taxonomic bacterial groups by NGS.  
340 DNA extraction was performed from faecal samples of mice belonging to the different  
341 experimental groups, collected at the end of each treatment. Preliminary analysis performed on  
342 samples collected at time point  $t_5$  (Figure 1), highlighted that microbiota composition of FD and  
343 C groups resulted homogeneous at the beginning of supplementation period (ANOVA  $\alpha$ -  
344 diversity  $P = 0.27$ ; PERMANOVA  $\beta$ -diversity  $P = 0.23$ ) (data not shown). Comparison of faecal  
345 bacterial communities at the end of treatments ( $t_{10}$ ), indicated significant variations of microbiota  
346 composition. A total of 564 OTUs were obtained from 8,331,582 quality-checked reads. The  
347 distributions of the OTU counts among samples were reported in supplementary Table S1 and  
348 are graphically depicted in Figure 3a.

349 Figure 3 reports the impact of diets on alpha diversity (Shannon index). The general picture  
350 shows higher values of Shannon index for the treatments M, FM and FFM with respect to C, FD

351 and R, highlighting the lowest variability for the FD and the highest variability for the FM  
352 bacterial communities. In particular, significant differences were observed for the contrasts FM  
353 vs FD (Padj < 0.001), M vs FD (Padj < 0.01), FFM vs FD (Padj < 0.001), R vs FM (Padj < 0.05),  
354 FM vs C (Padj < 0.05). Overall, these data indicate that supplementation with M, FM and FFM  
355 diets is associated to an increased species diversity.

356 The analysis of beta diversity, based on Bray-Curtis dissimilarity, revealed a significant effect of  
357 supplementations on bacterial community composition (Adonis,  $R^2= 0.435$  P= 0.001). The  
358 pairwise distance matrix, plotted in two dimensions through NMDS, clearly showed the  
359 clustering of samples according to treatments (Figure 4): along the first dimension, a cluster  
360 formed by the bacterial communities of the C, FD and R groups significantly differed from the  
361 other three clusters represented by the M, FM and FFM groups. These latter, along the second  
362 dimension, significantly differed among each other (Supplementary Table S2). These findings  
363 demonstrate that the three food matrices used for supplementation determined significant and  
364 specific variations in microbiota composition with respect to C, FD or R diets. On the other  
365 hand, FD diet did not significantly affect faecal bacterial community, which was similar to C and  
366 R samples (Figure 4).

367 Taxonomical assignments of the reads at the *phylum* level showed homogeneous bacterial  
368 composition within the groups, although slight inter-individual variability was observed (Figure  
369 5). *Actinobacteria*, *Bacteroidetes*, *Deferribacteres*, *Firmicutes* and *Verrucomicrobia* were  
370 detected as predominant bacterial phyla, with different relative proportions in each  
371 supplementation group. *Firmicutes* represented the most abundant phylum in all groups, with  
372 relative abundance ranging from 58 to 94% in the different samples (Figure 5). Moving through  
373 the taxonomic hierarchy at the genus level, 21 different genera were identified, and in addition to  
374 these, 11 unassigned genera belonging to different families or orders were reported  
375 (Supplementary file 1).

376 Discriminant taxa characterising each experimental group were identified on genus aggregated  
377 data by LEfSe analysis [43], allowing the detection of specific metagenomic biomarkers. Figure  
378 6 shows that C samples were characterised by *Aldercreutzia* and *Staphylococcus*, while FD  
379 samples were dominated by *Eubacterium*, *Coprobacillus* and *Clostridium*. Two additional  
380 bacterial groups were identified at the family level, namely *Erysipelotrichaceae* and  
381 *Clostridiaceae*. The R group was characterised by *Ruminococcus*, *Turicibacter* and  
382 *Mogibacteriaceae*, while *Oscillospira*, *Coprococcus* and *Clostridiales* characterised M samples.  
383 The groups of samples supplemented with FM and FFM milks were dominated by *Lactobacillus*,  
384 *Holdemania*, *Ruminococcaceae*, *Parabacteroides*, and *Dehalobacterium*, *Streptococcus*,



385 *Lachnospiraceae*, respectively. Interestingly, one of the biomarker genera associated to FFM  
386 was represented by *Streptococcus*, which was present exclusively in this group (Supplementary  
387 file 1) while *Lactobacillus* was one of the specific biomarkers of FM group. Although not  
388 representing a direct evidence, these findings suggest the possibility that the bacterial strains  
389 employed for fermentation could be able to reach the GI tract of supplemented mice.  
390

## 391 **Discussion**

392 Several studies highlighted a correlation between folic acid deficiency and high plasma Hcy  
393 concentration, which is considered as a risk factor for various multifactorial diseases [1]. The  
394 present work was performed in hyperhomocysteinemic mice with the aim of evaluating the effect  
395 of the supplementation with milk or fermented milks enriched in natural folates produced by  
396 suitably selected LAB, in comparison with the supplementation with synthetic folic acid. In  
397 order to induce hyperhomocysteinemia, mice were fed a diet depleted in folic acid and choline,  
398 and containing reduced levels of methionine, because of the metabolic interdependency of these  
399 three nutrients [45,46]. High plasma levels of Hcy detected in FD mice clearly demonstrated the  
400 efficacy of our experimental design to induce hyperhomocysteinemia.

401 The milk-based fermented food matrices employed for supplementation were set up to obtain  
402 products enriched in natural folate content as well as high in bacterial titers. Dairy products can  
403 be considered an adequate matrix to vehicle natural folate through ingestion, as folate-binding  
404 proteins (FBPs) in milk improve folate stability and the bioavailability of 5-MTHF [47].  
405 Together with 10-formyl-THF, 5-MTHF represents one of the major forms of folate synthesised  
406 by bacteria and the most common substrate for intracellular metabolic reactions [48]. Although  
407 the role of these FBPs is still unclear [49], it has been hypothesised that they can act by  
408 increasing the absorption efficiency of folate introduced through the diet, protecting folate from  
409 the degradation by gut microbiota [50]. While free folate is absorbed in the jejunum, the FBP-  
410 linked form is mainly absorbed in the ileum, at a much slower rate than free folate, increasing the  
411 absorption of folate by the host in the small intestine [51].

412 Newly isolated strains of *Lactobacillus helveticus*, *L. delbrueckii* and *Streptococcus*  
413 *thermophilus* selected for their ability to produce folate were employed for the production of  
414 fermented foods used in this work to supplement hyperhomocysteinemic mice. FFM supplement,  
415 enriched in folate, was obtained by co-cultivation of *L. delbrueckii* 1021 and *S. thermophilus* 563  
416 [32], while FM was fermented by *L. helveticus* 989 strain, which produced lower folate  
417 quantities. Although several studies have shown that *Lactobacillus* species tend to consume  
418 folates, the use of co-cultures of *S. thermophilus* and lactobacilli have been successfully  
419 employed to produce increased levels of folate [48,52]. The amount of folate detected in FFM  
420 confirmed this previous observation.

421 In our experimental design, all B vitamins involved in homocysteine metabolism were adequate  
422 in content, therefore hyperhomocysteinemia represents mainly a consequence of folate  
423 deficiency reduction. Surprisingly, despite their different folate content, higher in FFM with  
424 respect to FM and M, the administration of the three food matrices was able to resolve  
425 hyperhomocysteinemia, restoring plasma Hcy to the levels detected in C mice. However, the

426 results obtained on hepatic SAM levels suggest a different scenario. As already mentioned, SAM  
427 is the methyl donor for all methylation reactions, but it is also an important regulator that,  
428 depending on its concentration, drives the metabolic cycle to the trans-sulfuration or  
429 remethylation pathways. In fact, when present in high concentrations, SAM allosterically binds  
430 CBS, thus activating the trans-sulfuration pathway [53,54], since there is no need of additional  
431 methionine synthesis. Analysis of hepatic SAM levels highlighted differences among the three  
432 dairy matrices employed for supplementation of hyperhomocysteinemic mice. The high  
433 concentration of SAM detected in mice supplemented with FM and M diets suggests that the  
434 homocysteine recovery observed in these groups could be determined by the activation of trans-  
435 sulfuration pathway rather than re-methylation pathway, according to the role of SAM as a  
436 regulator of CBS activity. Indeed, our results showed that FFM exerts a different effect on SAM  
437 levels with respect to FM and M diets, suggesting that the higher folate content in FFM is  
438 adequate to remove the excess of homocysteine also via re-methylation pathway, as occurs  
439 following C and R supplementations. It must be pointed out that the amount of natural folate  
440 present in FFM is significantly lower than that in C and R diets (where it was supplied as  
441 synthetic folic acid), highlighting the effectiveness of natural folates. Accordingly, other authors  
442 have shown that natural folate produced by microbial fermentation is more effective than  
443 synthetic folic acid, as natural folate is absorbed and transported more easily into the body  
444 [51,55]. The efficacy of natural folates produced by bacteria has also been reported in a study  
445 conducted on rats supplemented with engineered strains of probiotic, folate-producing  
446 *Lactococcus lactis* which were able to counteract diet-induced folate deficiency by increasing  
447 plasma folate concentration, as compared to synthetic folic acid [26].

448 A parallel aim of our study concerned the impact of hyperhomocysteinemia and the subsequent  
449 supplementations on gut microbiota biodiversity. NGS analysis identified that faecal microbiota  
450 of mice supplemented with FFM, FM and M were characterised by a higher richness of bacterial  
451 species in comparison with C, FD and R groups, as revealed by Shannon index. The association  
452 between microbiota biodiversity and health [56] suggests possible beneficial effect of the dairy  
453 matrices employed in this study. The analysis of beta diversity, based on Bray-Curtis  
454 dissimilarity, highlighted the existence of a clear effect of the supplementations on gut bacterial  
455 community compositions. On the other hand, hyperhomocysteinemia was not associated with  
456 significant changes in faecal microbiota composition. No differences among C, FD and R groups  
457 were indeed observed, while the three dairy matrices determined specific significant variations in  
458 microbiota composition in supplemented mice.

459 We took advantage of LEfSe analysis, a promising tool to identify metagenomic biomarkers  
460 [43], to detect bacterial genera characterising each group. One interesting outcome of this  
461 analysis was the identification of *Streptococcus* and *Lactobacillus* as specific biomarkers  
462 characterising FFM and FM groups, respectively. This observation opens the possibility to  
463 perform further studies aimed at evaluating the potential gut colonisation capacity of the  
464 bacterial strains utilised for the fermentation processes. Indeed, an important aspect related to the  
465 capability of the diet to modulate the composition of the intestinal microbiota is the contribution  
466 of allochthonous bacteria, that can colonise the GI tract for a limited period of time, through the  
467 consumption of fermented products or probiotic formulations. In particular, LAB and  
468 bifidobacteria, representing common components of fermented food microbiota, may have  
469 probiotic features, including gut colonisation capacity [57]. Vitamin-producing probiotics may  
470 provide a complementary endogenous source of biomolecules that are not synthesised by  
471 mammalian cells, ensuring an adequate support [58]. Several studies addressed potential  
472 intervention strategies based on probiotics to counteract nutritional disorders associated to  
473 cardiovascular diseases and diabetes, such as obesity, hypercholesterolemia, arterial  
474 hypertension [59], considering that most of the randomised trials on vitamin and mineral  
475 supplementation did not show any evident benefits on chronic disease prevention. However, it is  
476 important to take into account the key role played by the food matrix in delivering health-  
477 promoting bacteria, protecting them from the harsh conditions of the upper GI tract and  
478 consequently enhancing their colonisation capacity. Regular consumption of fermented dairy  
479 products rather than the specific intake of probiotics was shown to increase B-vitamins levels in  
480 human subjects [60].

481 LEfSe analysis also indicated that the genera *Eubacterium*, *Coprobacillus*, *Clostridium* and  
482 *Erysipelotrichaceae* characterise the FD group, suggesting a possible link between these  
483 bacterial groups and hyperhomocysteinemia. It is interesting to note that altered levels of  
484 *Erysipelotrichi* have been previously reported to be associated to a choline-deficient diet [61,62].  
485 However, more studies are needed to further investigate the role of specific gut microbes in folic  
486 acid deficiency and high plasma Hcy levels as well as the effect of long term treatment with  
487 functional fermented products on the prevention of cardiovascular and neurological diseases.  
488 The possible relationships between the presence of bacterial "biomarkers" and  
489 hyperhomocysteinemia, as well as the possible implications of such microorganisms in folate  
490 metabolism, are currently under investigation in our laboratories.

491

492 **References**

- 493 1. Strain JJ, Dowey L, Ward M, Pentieva K, McNulty H (2004) B-vitamins, homocysteine  
 494 metabolism and CVD. *Proc Nutr Soc* 63 (4):597-603. doi:S0029665104000801 [pii]
- 495 2. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, Lewis MJ  
 496 (1998) Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in  
 497 healthy adults. *Circulation* 98 (18):1848-1852
- 498 3. Appel LJ, Miller ER, 3rd, Jee SH, Stolzenberg-Solomon R, Lin PH, Erlinger T, Nadeau MR,  
 499 Selhub J (2000) Effect of dietary patterns on serum homocysteine: results of a randomized, controlled  
 500 feeding study. *Circulation* 102 (8):852-857
- 501 4. Bissoli L, Di Francesco V, Ballarin A, Mandragona R, Trespidi R, Brocco G, Caruso B, Bosello  
 502 O, Zamboni M (2002) Effect of vegetarian diet on homocysteine levels. *Ann Nutr Metab* 46 (2):73-79.  
 503 doi:57644 [pii] 10.1159/000057644
- 504 5. Mann NJ, Li D, Sinclair AJ, Dudman NP, Guo XW, Elsworth GR, Wilson AK, Kelly FD (1999)  
 505 The effect of diet on plasma homocysteine concentrations in healthy male subjects. *Eur J Clin Nutr* 53  
 506 (11):895-899
- 507 6. Jamwal S, Sharma S (2018) Vascular endothelium dysfunction: a conservative target in metabolic  
 508 disorders. *Inflamm Res*. doi:10.1007/s00011-018-1129-8 10.1007/s00011-018-1129-8 [pii]
- 509 7. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB (2016) Folic Acid Supplementation and the  
 510 Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. *J Am Heart Assoc* 5  
 511 (8). doi:JAHA.116.003768 [pii] 10.1161/JAHA.116.003768
- 512 8. Huang X, Li Y, Li P, Li J, Bao H, Zhang Y, Wang B, Sun N, Wang J, He M, Yin D, Tang G,  
 513 Chen Y, Cui Y, Huang Y, Hou FF, Qin X, Huo Y, Cheng X (2017) Association between percent decline  
 514 in serum total homocysteine and risk of first stroke. *Neurology* 89 (20):2101-2107.  
 515 doi:WNL.0000000000004648 [pii] 10.1212/WNL.0000000000004648
- 516 9. Marti-Carvajal AJ, Sola I, Lathyris D, Dayer M (2017) Homocysteine-lowering interventions for  
 517 preventing cardiovascular events. *Cochrane Database Syst Rev* 8:CD006612.  
 518 doi:10.1002/14651858.CD006612.pub5
- 519 10. Zhang DM, Ye JX, Mu JS, Cui XP (2017) Efficacy of Vitamin B Supplementation on Cognition  
 520 in Elderly Patients With Cognitive-Related Diseases. *J Geriatr Psychiatry Neurol* 30 (1):50-59.  
 521 doi:10.1177/0891988716673466
- 522 11. Zhou Z, Liang Y, Qu H, Zhao M, Guo F, Zhao C, Teng W (2018) Plasma homocysteine  
 523 concentrations and risk of intracerebral hemorrhage: a systematic review and meta-analysis. *Sci Rep* 8  
 524 (1):2568. doi:10.1038/s41598-018-21019-3 10.1038/s41598-018-21019-3 [pii]
- 525 12. Konings EJ, Roomans HH, Dorant E, Goldbohm RA, Saris WH, van den Brandt PA (2001)  
 526 Folate intake of the Dutch population according to newly established liquid chromatography data for  
 527 foods. *Am J Clin Nutr* 73 (4):765-776
- 528 13. Smith AD, Kim YI, Refsum H (2008) Is folic acid good for everyone? *Am J Clin Nutr* 87  
 529 (3):517-533. doi:87/3/517 [pii]
- 530 14. Bailey SW, Ayling JE (2009) The extremely slow and variable activity of dihydrofolate reductase  
 531 in human liver and its implications for high folic acid intake. *Proc Natl Acad Sci U S A* 106 (36):15424-  
 532 15429. doi:0902072106 [pii] 10.1073/pnas.0902072106
- 533 15. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, Selhub J, McTiernan A,  
 534 Yasui Y, Oral E, Potter JD, Ulrich CM (2006) Unmetabolized folic acid in plasma is associated with  
 535 reduced natural killer cell cytotoxicity among postmenopausal women. *J Nutr* 136 (1):189-194.  
 536 doi:136/1/189 [pii]
- 537 16. Sawaengsri H, Wang J, Reginaldo C, Steluti J, Wu D, Meydani SN, Selhub J, Paul L (2016) High  
 538 folic acid intake reduces natural killer cell cytotoxicity in aged mice. *J Nutr Biochem* 30:102-107.  
 539 doi:S0955-2863(16)00003-6 [pii] 10.1016/j.jnutbio.2015.12.006
- 540 17. Melnyk S, Pogribna M, Miller BJ, Basnakian AG, Pogribny IP, James SJ (1999) Uracil  
 541 misincorporation, DNA strand breaks, and gene amplification are associated with tumorigenic cell  
 542 transformation in folate deficient/repleted Chinese hamster ovary cells. *Cancer Lett* 146 (1):35-44.  
 543 doi:S030438359900213X [pii]
- 544 18. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, Rosenberg IH (2007) A  
 545 temporal association between folic acid fortification and an increase in colorectal cancer rates may be

546 illuminating important biological principles: a hypothesis. *Cancer Epidemiol Biomarkers Prev* 16  
547 (7):1325-1329. doi:16/7/1325 [pii] 10.1158/1055-9965.EPI-07-0329

548 19. Hirsch S, Sanchez H, Albala C, de la Maza MP, Barrera G, Leiva L, Bunout D (2009) Colon  
549 cancer in Chile before and after the start of the flour fortification program with folic acid. *Eur J*  
550 *Gastroenterol Hepatol* 21 (4):436-439. doi:10.1097/MEG.0b013e328306ccdb

551 20. Baggott JE, Oster RA, Tamura T (2012) Meta-analysis of cancer risk in folic acid  
552 supplementation trials. *Cancer Epidemiol* 36 (1):78-81. doi:S1877-7821(11)00084-1 [pii]  
553 10.1016/j.canep.2011.05.003

554 21. Christensen KE, Mikael LG, Leung KY, Levesque N, Deng L, Wu Q, Malysheva OV, Best A,  
555 Caudill MA, Greene ND, Rozen R (2015) High folic acid consumption leads to pseudo-MTHFR  
556 deficiency, altered lipid metabolism, and liver injury in mice. *Am J Clin Nutr* 101 (3):646-658.  
557 doi:ajcn.114.086603 [pii] 10.3945/ajcn.114.086603

558 22. Asrar FM, O'Connor DL (2005) Bacterially synthesized folate and supplemental folic acid are  
559 absorbed across the large intestine of piglets. *J Nutr Biochem* 16 (10):587-593. doi:S0955-  
560 2863(05)00055-0 [pii] 10.1016/j.jnutbio.2005.02.006

561 23. LeBlanc JG, Laino JE, del Valle MJ, Vannini V, van Sinderen D, Taranto MP, de Valdez GF, de  
562 Giori GS, Sesma F (2011) B-group vitamin production by lactic acid bacteria--current knowledge and  
563 potential applications. *J Appl Microbiol* 111 (6):1297-1309. doi:10.1111/j.1365-2672.2011.05157.x

564 24. Saubade F, Hemery YM, Guyot JP, Humblot C (2017) Lactic acid fermentation as a tool for  
565 increasing the folate content of foods. *Crit Rev Food Sci Nutr* 57 (18):3894-3910.  
566 doi:10.1080/10408398.2016.1192986

567 25. Pompei A, Cordisco L, Amaretti A, Zanoni S, Raimondi S, Matteuzzi D, Rossi M (2007)  
568 Administration of folate-producing bifidobacteria enhances folate status in Wistar rats. *J Nutr* 137  
569 (12):2742-2746. doi:137/12/2742 [pii]

570 26. LeBlanc JG, Sybesma W, Starrenburg M, Sesma F, de Vos WM, de Giori GS, Hugenholtz J  
571 (2010) Supplementation with engineered *Lactococcus lactis* improves the folate status in deficient rats.  
572 *Nutrition* 26 (7-8):835-841. doi:S0899-9007(09)00298-6 [pii]10.1016/j.nut.2009.06.023

573 27. Iyer R, Tomar SK (2011) Dietary effect of folate-rich fermented milk produced by *Streptococcus*  
574 *thermophilus* strains on hemoglobin level. *Nutrition* 27 (10):994-997. doi:S0899-9007(11)00039-6 [pii]  
575 10.1016/j.nut.2011.01.003

576 28. D'Aimmo MR, Mattarelli P, Biavati B, Carlsson NG, Andlid T (2012) The potential of  
577 bifidobacteria as a source of natural folate. *J Appl Microbiol* 112 (5):975-984. doi:10.1111/j.1365-  
578 2672.2012.05261.x

579 29. Laino JE, H Z, MJ dV, Savoy de Giori G, Leblanc JG (2015) Milk fermented with selected strains  
580 of lactic acid bacteria is able to improve folate status of deficient rodents and also prevent folate  
581 deficiency. *J Funct Foods* 17:22-32

582 30. LeBlanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M (2013) Bacteria as  
583 vitamin suppliers to their host: a gut microbiota perspective. *Curr Opin Biotechnol* 24 (2):160-168.  
584 doi:S0958-1669(12)00119-X [pii]10.1016/j.copbio.2012.08.005

585 31. Bouzas J, Kantt CA, Bodyfelt F, Torres JA (1991) Simultaneous determination of sugars and  
586 organic acids in Cheddar cheese by high performance liquid chromatography. *J Food Sci* 56:276}278

587 32. Meucci A, Rossetti L, Zago M, Monti L, Giraffa G, Carminati D, Tidona F (2018) Folates  
588 biosynthesis by *Streptococcus thermophilus* during growth in milk. *Food Microbiol* 69:116-122.  
589 doi:S0740-0020(17)30341-6 [pii]10.1016/j.fm.2017.08.001

590 33. Reeves PG (1997) Components of the AIN-93 diets as improvements in the AIN-76A diet. *J Nutr*  
591 127 (5 Suppl):838S-841S

592 34. Tuschl K, Bodamer OA, Erwa W, Muhl A (2005) Rapid analysis of total plasma homocysteine by  
593 tandem mass spectrometry. *Clin Chim Acta* 351 (1-2):139-141. doi:S0009-8981(04)00426-7 [pii]  
594 10.1016/j.cccn.2004.08.016

595 35. Struys EA, Jansen EE, de Meer K, Jakobs C (2000) Determination of S-adenosylmethionine and  
596 S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass  
597 spectrometry. *Clin Chem* 46 (10):1650-1656

598 36. Krijt J, Duta A, Kozich V (2009) Determination of S-Adenosylmethionine and S-  
599 Adenosylhomocysteine by LC-MS/MS and evaluation of their stability in mice tissues. *J Chromatogr B*  
600 *Analyt Technol Biomed Life Sci* 877 (22):2061-2066. doi:S1570-0232(09)00374-2 [pii]  
601 10.1016/j.jchromb.2009.05.039

602 37. Wagner Mackenzie B, Waite DW, Taylor MW (2015) Evaluating variation in human gut  
603 microbiota profiles due to DNA extraction method and inter-subject differences. *Front Microbiol* 6:130.  
604 doi:10.3389/fmicb.2015.00130

605 38. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena  
606 AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA,  
607 McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J,  
608 Yatsunencko T, Zaneveld J, Knight R (2010) QIIME allows analysis of high-throughput community  
609 sequencing data. *Nat Methods* 7 (5):335-336. doi:nmeth.f.303 [pii]  
610 10.1038/nmeth.f.303

611 39. Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, Mills DA, Caporaso JG  
612 (2013) Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. *Nat*  
613 *Methods* 10 (1):57-59. doi:nmeth.2276 [pii]10.1038/nmeth.2276

614 40. McMurdie PJ, Holmes S (2013) phyloseq: an R package for reproducible interactive analysis and  
615 graphics of microbiome census data. *PLoS One* 8 (4):e61217. doi:10.1371/journal.pone.0061217  
616 PONE-D-12-31789 [pii]

617 41. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlenn D, Minchin PR, O'Hara  
618 RB, Simpson GL, Solymos P, Stevens MHH, Szoecs E, Wagner H (2016) CRAN - Package vegan.

619 42. Anderson MJ (2001) A new method for non-parametric multivariate analysis of variance. *Austral*  
620 *Ecol* 26:32-46. doi:doi:10.1111/j.1442-9993.2001.01070.pp.x

621 43. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C (2011)  
622 Metagenomic biomarker discovery and explanation. *Genome Biol* 12 (6):R60. doi:gb-2011-12-6-r60 [pii]  
623 10.1186/gb-2011-12-6-r60

624 44. Zakrzewski M, Proietti C, Ellis JJ, Hasan S, Brion MJ, Berger B, Krause L (2017) Calypso: a  
625 user-friendly web-server for mining and visualizing microbiome-environment interactions.  
626 *Bioinformatics* 33 (5):782-783. doi:btw725 [pii]10.1093/bioinformatics/btw725

627 45. Velez-Carrasco W, Merkel M, Twiss CO, Smith JD (2008) Dietary methionine effects on plasma  
628 homocysteine and HDL metabolism in mice. *J Nutr Biochem* 19 (6):362-370. doi:S0955-2863(07)00137-  
629 4 [pii]10.1016/j.jnutbio.2007.05.005

630 46. Obeid R (2013) The metabolic burden of methyl donor deficiency with focus on the betaine  
631 homocysteine methyltransferase pathway. *Nutrients* 5 (9):3481-3495. doi:nu5093481  
632 [pii]10.3390/nu5093481

633 47. Jones ML, Nixon PF (2002) Tetrahydrofolates are greatly stabilized by binding to bovine milk  
634 folate-binding protein. *J Nutr* 132 (9):2690-2694. doi:10.1093/jn/132.9.2690

635 48. Laino JE, MJ dV, Savoy de Giori G, Leblanc JG (2013) Development of a high folate  
636 concentration yogurt naturally bio-enriched using selected lactic acid bacteria. *LWT-Food Science and*  
637 *Technology* 54:1-5

638 49. Forssen KM, Jagerstad MI, Wigertz K, Withoft CM (2000) Folate and dairy products: a critical  
639 update. *J Am Coll Nutr* 19 (2 Suppl):100S-110S

640 50. Eitenmiller RR, Landen WO (1999) Folate. In: Eitenmiller RRL, W.O. (ed) *Vitamin Analysis for*  
641 *the Health and Food Sciences*. CRC Press, Boca Raton, FL, pp 411-466

642 51. Said HM, Chatterjee N, Haq RU, Subramanian VS, Ortiz A, Matherly LH, Sirotnak FM, Halsted  
643 C, Rubin SA (2000) Adaptive regulation of intestinal folate uptake: effect of dietary folate deficiency.  
644 *Am J Physiol Cell Physiol* 279 (6):C1889-1895. doi:10.1152/ajpcell.2000.279.6.C1889

645 52. Rossi M, Amaretti A, Raimondi S (2011) Folate production by probiotic bacteria. *Nutrients* 3  
646 (1):118-134. doi:10.3390/nu3010118 nu3010118 [pii]

647 53. Janosik M, Kery V, Gaustadnes M, Maclean KN, Kraus JP (2001) Regulation of human  
648 cystathionine beta-synthase by S-adenosyl-L-methionine: evidence for two catalytically active  
649 conformations involving an autoinhibitory domain in the C-terminal region. *Biochemistry* 40 (35):10625-  
650 10633. doi:bi010711p [pii]

651 54. Ereno-Orbea J, Majtan T, Oyenarte I, Kraus JP, Martinez-Cruz LA (2014) Structural insight into  
652 the molecular mechanism of allosteric activation of human cystathionine beta-synthase by S-  
653 adenosylmethionine. *Proc Natl Acad Sci U S A* 111 (37):E3845-3852. doi:1414545111 [pii]  
654 10.1073/pnas.1414545111

655 55. Zhao R, Diop-Bove N, Visentin M, Goldman ID (2011) Mechanisms of membrane transport of  
656 folates into cells and across epithelia. *Annu Rev Nutr* 31:177-201. doi:10.1146/annurev-nutr-072610-  
657 145133

- 658 56. Mosca A, Leclerc M, Hugot JP (2016) Gut Microbiota Diversity and Human Diseases: Should  
659 We Reintroduce Key Predators in Our Ecosystem? *Front Microbiol* 7:455. doi:10.3389/fmicb.2016.00455
- 660 57. Vaughan EE, de Vries MC, Zoetendal EG, Ben-Amor K, Akkermans AD, de Vos WM (2002)  
661 The intestinal LABs. *Antonie Van Leeuwenhoek* 82 (1-4):341-352
- 662 58. Strozzi GP, Mogna L (2008) Quantification of folic acid in human feces after administration of  
663 *Bifidobacterium* probiotic strains. *J Clin Gastroenterol* 42 Suppl 3 Pt 2:S179-184.  
664 doi:10.1097/MCG.0b013e31818087d8
- 665 59. Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P, Gervais P (2014) Impact of  
666 probiotics on risk factors for cardiovascular diseases. A review. *Crit Rev Food Sci Nutr* 54 (2):175-189.  
667 doi:10.1080/10408398.2011.579361
- 668 60. Fabian E, Majchrzak D, Dieminger B, Meyer E, Elmadfa I (2008) Influence of probiotic and  
669 conventional yoghurt on the status of vitamins B1, B2 and B6 in young healthy women. *Ann Nutr Metab*  
670 52 (1):29-36. doi:000114408 [pii]10.1159/000114408
- 671 61. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA (2011) Association between  
672 composition of the human gastrointestinal microbiome and development of fatty liver with choline  
673 deficiency. *Gastroenterology* 140 (3):976-986. doi:S0016-5085(10)01739-7  
674 [pii]10.1053/j.gastro.2010.11.049
- 675 62. Holmes E, Li JV, Marchesi JR, Nicholson JK (2012) Gut microbiota composition and activity in  
676 relation to host metabolic phenotype and disease risk. *Cell Metab* 16 (5):559-564. doi:S1550-  
677 4131(12)00407-X [pii]10.1016/j.cmet.2012.10.007
- 678 63. Leinonen R, Akhtar R, Birney E, Bower L, Cerdeno-Tarraga A, Cheng Y, Cleland I, Faruque N,  
679 Goodgame N, Gibson R, Hoad G, Jang M, Pakseresht N, Plaister S, Radhakrishnan R, Reddy K, Sobhany  
680 S, Ten Hoopen P, Vaughan R, Zalunin V, Cochrane G (2011) The European Nucleotide Archive. *Nucleic  
681 Acids Res* 39 (Database issue):D28-31. doi:gkq967 [pii]10.1093/nar/gkq967



682 **Acknowledgments**

683 The Authors wish to thank Kariklia Pascucci for her kind support in daily lab work, Altero  
684 Aguzzi for his help in fermented milk liophylisation and Rita Rami for the excellent care of the  
685 animals. This work was funded by the Italian Ministry of Agriculture, Food & Forestry Policies  
686 (MiPAAF), with grant “MEDITO” (DM 12487/7303/11) and with national support to the JPI-  
687 HDHL “ENPADASI” project.

688

689 **Conflict of interests**

690 The authors declare that they have no conflict of interests.

691

692 **Availability of data and materials**

693 Raw NGS data are available at the EMBL-EBI European Nucleotide Archive (ENA) [63], under  
694 the study accession number PRJEB24434.

695

696 **Consent for publication**

697 All authors read and approved the final manuscript.

698

699 **Figure captions**

700  
701 **Fig. 1** Experimental design. Arrows indicate the different diets: standard diet (white arrow);  
702 control diet (black arrow); folate deficient diet (light grey arrow); supplemented folate deficient  
703 diet (dark grey arrow). C: Control; FD: Folate Deficient, FFM: Folate Fermented Milk; FM:  
704 Fermented Milk; M: Milk; R: Repleted. Time is expressed as weeks and it is represented by a  
705 line. Dashed line refers to the adaptation period of one week, prior to the application of the  
706 feeding protocol aimed at inducing hyperhomocysteinemia and including control diet. At the end  
707 of the experimental period, blood was collected and faeces were sampled for gut microbiota  
708 analysis. The time points are indicated as:  $t_a$  (beginning of adaptation),  $t_0$  (beginning of  
709 treatments),  $t_5$  (shift to supplementation),  $t_{10}$  (end of treatments).

710  
711 **Fig. 2.** Plasma homocysteine and liver SAM levels. Box plot representation of plasma  
712 homocysteine concentrations (a), expressed as  $\mu\text{M}$ , and liver SAM amounts (b) expressed as  
713 pmol/mg tissue, for the different experimental groups (C, FD, FFM, FM, M and R). Data were  
714 analysed through ANOVA followed by *post hoc* Tukey test ( $P < 0.0001$ ). Different letters  
715 indicate significant differences.

716  
717 **Fig. 3** Alpha diversity of faecal samples. Box plot of the Observed OTUs abundances and  
718 Shannon index values. Samples are grouped according to the different treatments (C, FD, FFM,  
719 FM, M and R). The asterisks indicate significant differences (Tukey-Kramer test): \* =  $P < 0.05$ ,  
720 \*\* =  $P < 0.01$ , \*\*\* =  $P < 0.001$  (P values adjusted by Benjamini & Hochberg correction).


721  
722 **Fig. 4** NMDS analysis of faecal samples. Non-metric multidimensional scaling plot of Bray-  
723 Curtis distances. Samples are grouped according to the different treatments (C, FD, FFM, FM, M  
724 and R).

725  
726 **Fig. 5** Relative abundance of gut bacterial phyla obtained by NGS of faecal samples. Each bar  
727 refers to a single faecal sample and depicts the proportion of OTUs per sample, expressed as  
728 percentage. Colour coding of bacterial phyla is shown on the right side. “Others” includes  
729 unidentified microorganisms of Bacteria kingdom and unclassified microorganisms. Samples are  
730 grouped according to the different treatments (C, FD, FFM, FM, M and R).

731

732 **Fig. 6.** LEfSe analysis of faecal samples. Discriminant taxa (genus aggregated) identified by  
733 linear discriminant analysis (LDA) effect size (LEfSe). Samples are grouped according to the  
734 different treatments (C, FD, FFM, FM, M and R).

735  
736 **Fig. S1.** Per sample rarefaction curves. Each curve shows the average number of OTUs  
737 (Operational Taxonomic Units) as a function of the reads abundance subsampled at different  
738 depths. Each frame and color represent the experimental treatments, the vertical gray line  
739 indicates the lowest number of reads obtained on overall samples ( $n = 76187$ ).






Figure 3




Figure 4





Figure 5

[Click here to access/download;Figure;Fig5.tif](#)





Figure 6



**Table 1. Diet compositions**

<i>Ingredient</i>	<i>Control Diet<sup>a</sup></i>	<i>Folate Deficient Diet</i> (g/Kg)	<i>Supplemented Diet</i>
Mais starch	467.5	468.2	189
Aminoacid mix	140	-	-
Aminoacid mix (methionine free)	-	140	-
Lyophilized milk <sup>b</sup>	-	-	420
Maltodextrin	155	155	155
Sucrose	100	100	100
Soya oil	40	40	40
Cellulose	50	50	50
Mineral mix	35	35	35
Vitamin mix <sup>c</sup>	10	-	-
Vitamin mix (folate free)	-	10	10
Choline chloride	2.5	-	-
Methionine	-	1.8	1.5
tert-Butylhydroquinone	0.008	0.008	0.008

<sup>a</sup>AIN-93M, modified by substitution of casein with casein-like aminoacid mix

<sup>b</sup>FFM, FM or M milk was added according to the supplementation group. Folate content in FFM, FM and M was 0.29, 0.08 and 0.07 mg/kg diet, respectively

<sup>c</sup>Folic acid amount in Vitamin mix was 2 mg/kg diet

**Table 2. Fermented and control milk composition**

	<b>Bacterial strain</b>	<b>Bacterial titer (log<sub>10</sub> CFU/ml)</b>	<b>pH</b>	<b>Lactose (g/100g)</b>	<b>Glucose (g/100g)</b>	<b>Galactose (g/100g)</b>	<b>Citric acid (g/100g)</b>	<b>Lactic acid (g/100g)</b>	<b>Folate (ng/g)</b>
<b>FFM</b>	<i>S. thermophilus</i> 563	9.10 ±0.01 <sup>a</sup>	3.89	2.57 ±0.02 <sup>a</sup>	0.00 ±0.00	1.06 ±0.56 <sup>a</sup>	0.24 ±0.01	1.24 ±0.01 <sup>a</sup>	70.33 ±15.44 <sup>a</sup>
	<i>L. delbrueckii</i> 1021	8.48 ±0.03 <sup>b</sup>							
<b>FM</b>	<i>L. helveticus</i> 989	8.26 ±0.04 <sup>b</sup>	3.77	3.37 ±0.02 <sup>b</sup>	0.20 ±0.01	0.08 ±0.00 <sup>b</sup>	0.19 ±0.01	1.29 ±0.02 <sup>a</sup>	19.40 ±8.77 <sup>b</sup>
<b>M</b>	-	nd	6.60	4.35 ±0.01 <sup>c</sup>	0.00 ±0.00	0.05 ±0.00 <sup>b</sup>	0.22 ±0.02	0.00 ±0.01	16.90 ±0.31 <sup>b</sup>

Analyses were performed on fresh food matrices before freezing and lyophilisation.

nd: not determined

Values with different superscript letters differ significantly.

**Table 3. Body weight and food consumption from C, FD, R, FFM, FM or M mice.**


	<b>C</b>	<b>FD</b>	<b>R</b>	<b>FFM</b>	<b>FM</b>	<b>M</b>
Body weight (g)						
Initial	19.1 ± 2.6	19.9 ± 3.0	18.6 ± 2.3	17.8 ± 2.7	17.9 ± 2.4	16.8 ± 2.0
Final	37.6 ± 3.1	37.4 ± 3.6	37.9 ± 2.6	33.4 ± 5.2	35.5 ± 4.3	37.0 ± 2.8
Gain (%)	99.7 ± 28.8	90.0 ± 17.8	105.6 ± 23.3	91.2 ± 38.8	102.1 ± 40.9	122.8 ± 23.4
Food intake (g/day)	4.1 ± 0.3 <sup>ab</sup>	4.0 ± 0.3 <sup>a</sup>	4.2 ± 0.4 <sup>a,b</sup>	4.3 ± 0.2 <sup>ab</sup>	4.3 ± 0.2 <sup>b</sup>	4.1 ± 0.2 <sup>a,b</sup>


Values represent mean ± SD. Different letters indicate significant differences ( $P < 0.05$ ).



Click here to access/download



**Electronic Supplementary Material**  
Table S1.docx





Click here to access/download

**Electronic Supplementary Material**  
Table S2.docx





[Click here to access/download](#)

**Electronic Supplementary Material**  
FigS1.tif





[Click here to access/download](#)

**Electronic Supplementary Material**  
Supplementary file 1new.xlsx

